β-Catenin Expression and Its Association with Prognostic Factors in Hepatocellular Carcinoma: A Study on Alpha-fetoprotein, Histologic Grade, and Microvascular Invasion
DOI:
https://doi.org/10.3889/oamjms.2021.6123Keywords:
β-catenin, Hepatocellular carcinoma, Alphafetoprotein, Microvascular invasion, Tumor gradeAbstract
Background. Hepatocellular carcinoma (HCC), the most common primary liver cancer. In addition to its high incidence, the disease burden is high due to its poor prognosis and high recurrence rate. Some of the currently known clinicopathologic prognostic factors include alpha-fetoprotein (AFP) level, histologic grade, and microvascular invasion. At the molecular level, β-catenin is one of the most common driver mutation found in HCC. The Wnt/β-catenin pathway regulates cellular processes related to initiation, growth, survival, migration, differentiation, and apoptosis. Although the underlying pathogenesis of hepatocarcinogenesis is known, clinical application warrants a greater understanding of the molecular characteristics and tumor phenotype, especially for determining the prognosis. This study aims to analyze the expression of β-catenin and its association with AFP, histologic grade, and microvascular invasion. Materials and methods. Thirty-five samples of surgically resected HCCs at Cipto Mangunkusumo National Referral Hospital were examined. Diagnoses were made based on histopathological and immunohistochemical findings followed by β-catenin staining. β-catenin expression was analyzed to determine difference between variables. Results and conclusions. Here we show that β-catenin expression is significantly associated with low serum alpha-fetoprotein and well to moderate differentiation Implications. Strong nuclear β-catenin expression implies better prognosis in HCC.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Johnson P. The epidemiology of hepatocellular carcinoma. In: Cross T, Palmer D, editors. Liver Cancers. Switzerland: Springer; 2019. p. 3-11. DOI: https://doi.org/10.1007/978-3-319-92216-4_1
Torbenson MS, Ng IO, Park YN, Roncalli M, Sakamoto M. Hepatocellular carcinoma. In: Paradis V, Fukayama M, Park YN, Schirmacher P, editors. WHO Classification of Digestive System Tumours. Lyon: International Agency for Research on Cancer; 2019.
Theise ND, Curado MPF, Hytiroglou SP, Franceschi S, Kudo M, Park Y N, Sakamoto M, et al. Hepatocellular carcinoma. In: Bosman FT, Cameiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer; 2010. p. 205-16.
Kementerian Kesehatan Republik Indonesia, Hari Kanker Sedunia 2019; 2019. Available from: http://www.depkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html. [Last accessed on 2021 Mar 10].
Indonesian Liver Cancer Study Group. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: Perhimpunan Peneliti Hati Indonesia; 2017.
Unal E, Idilman IS, Akata D, Ozmen MN, Karcaaltincaba M. Microvascular invasion in hepatocellular carcinoma. Diagn Interv Radiol. 2016;22(2):125-32. https://doi.org/10.5152/dir.2015.15125 PMid:26782155 DOI: https://doi.org/10.5152/dir.2015.15125
Tateishi R, Shiina H, Yoshida H, Teratani T, Obi S, Yamashiki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006;44(6):1518-27. https://doi.org/10.1002/hep.21408 PMid:17133456 DOI: https://doi.org/10.1002/hep.21408
Han DH, Choi GH, Kim KS, Choi JS, Park YN, Kim SU, et al. Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. J Gastroenterol Hepatol. 2013;28(8):1384-90. https://doi.org/10.1111/jgh.12200 PMid:23517197 DOI: https://doi.org/10.1111/jgh.12200
Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254(1):108-13. https://doi.org/10.1097/sla.0b013e31821ad884 PMid:21527845 DOI: https://doi.org/10.1097/SLA.0b013e31821ad884
Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727-38. https://doi.org/10.1016/j.jhep.2017.05.014 PMid:28532995 DOI: https://doi.org/10.1016/j.jhep.2017.05.014
Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42-52. https://doi.org/10.1002/hep.21467 PMid:17187432 DOI: https://doi.org/10.1002/hep.21467
Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61-73. https://doi.org/10.2147/jhc.s156701 Mid:29984212 DOI: https://doi.org/10.2147/JHC.S156701
Sasaki K, Matsuda M, Ohkura Y, Kawamura Y, Inoue M, Hashimoto M, et al. In hepatocellular carcinomas, any proportion of poorly differentiated components is associated with poor prognosis after hepatectomy. World J Surg 2014;38(5):1147-53. https://doi.org/10.1007/s00268-013-2374-1 PMid:24305929 DOI: https://doi.org/10.1007/s00268-013-2374-1
Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci. 1999;112(8):1237-45. PMid:10085258 DOI: https://doi.org/10.1242/jcs.112.8.1237
Verma A, Bal M, Ramadwar M, Deodhar K, Pati P, Goel M. Clinicopathologic characteristics of Wnt/β-catenin-deregulated hepatocellular carcinoma. Indian J Cancer. 2017;54(4):634-9. https://doi.org/10.4103/ijc.ijc_655_17 PMid:30082549 DOI: https://doi.org/10.4103/ijc.IJC_655_17
Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol. 2001;193(1):95-101. https://doi.org/10.1002/1096-9896(2000)9999:9999<::aid-path720>3.0.co;2-3 PMid:11169521 DOI: https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3
Chen J, Liu J, Jin R, Shen J, Liang Y, Ma R, et al. Cytoplasmic and/ or nuclear expression of β-catenin correlate with poor prognosis and unfavorable clinicopathological factors in hepatocellular carcinoma: A meta-analysis. PLoS One. 2014;9(11):e111885. https://doi.org/10.1371/journal.pone.0111885 PMid:25401330 DOI: https://doi.org/10.1371/journal.pone.0111885
Joo M, Lee HK, Kang YK. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. J Korean Med Sci. 2003;18(2):211-7. https://doi.org/10.3346/jkms.2003.18.2.211 PMid:12692418 DOI: https://doi.org/10.3346/jkms.2003.18.2.211
Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155(3):703-10. https://doi.org/10.1016/s0002-9440(10)65168-1 PMid:10487827 DOI: https://doi.org/10.1016/S0002-9440(10)65168-1
Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157(3):763-70. https://doi.org/10.1016/s0002-9440(10)64590-7 PMid:10980116 DOI: https://doi.org/10.1016/S0002-9440(10)64590-7
Tien LT, Ito M, Nakao M, Niino D, Serik M, Nakashima M, et al. Expression of beta-catenin in hepatocellular carcinoma. World J Gastroenterol. 2005;11(16):2398-401. PMid:15832407 DOI: https://doi.org/10.3748/wjg.v11.i16.2398
Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer. 2008;7(1):21. https://doi.org/10.1186/1476-4598-7-21 PMid:18282277 DOI: https://doi.org/10.1186/1476-4598-7-21
Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999;155(6):1795-801. https://doi.org/10.1016/s0002-9440(10)65496-x PMid:10595907 DOI: https://doi.org/10.1016/S0002-9440(10)65496-X
Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002;8(2):450-6. PMid:11839663
Wong CM, Fan ST, Ng IO. Beta-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer. 2001;92(1):136-45. https://doi.org/10.1002/1097-0142(20010701)92:1<136::aid-cncr1301>3.0.co;2-r PMid:11443619 DOI: https://doi.org/10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R
El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):S72-8. PMid:12394209 DOI: https://doi.org/10.1097/00004836-200211002-00002
Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver. 2016;10(3):332-9. https://doi.org/10.5009/gnl15257 PMid:27114433 DOI: https://doi.org/10.5009/gnl15257
Keng VW, Largaespada DA, Villaneuva A. Why men are at higher risk for hepatocellular carcinoma? J Hepatol. 2012;57(2):453-4. PMid:22425699 DOI: https://doi.org/10.1016/j.jhep.2012.03.004
Von Olhausen G, Quasdorff M, Bester R, Arzberger S, Ko C, van de Klundert M, et al. Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion. Oncotarget. 2018;9(74):33947-60. https://doi.org/10.18632/oncotarget.26103 PMid:30338037 DOI: https://doi.org/10.18632/oncotarget.26103
Rogacki K, Kasprzak A, Stepinski A. Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus. Pol J Pathol. 2015;66(1):9-21. https://doi.org/10.5114/pjp.2015.51148 PMid:26017875 DOI: https://doi.org/10.5114/pjp.2015.51148
Liu LJ, Xie SX, Chen YT, Xue JL, Zhang CJ, Zhu F. Aberrant regulation of Wnt signaling in hepatocellular carcinoma. World J Gastroenterol. 2016;22(33):7486-99. https://doi.org/10.3748/wjg.v22.i33.7486 PMid:27672271 DOI: https://doi.org/10.3748/wjg.v22.i33.7486
Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal. Dig Liver Dis. 2010;42(5):341-7. https://doi.org/10.1016/j.dld.2009.09.002 PMid:19828388 DOI: https://doi.org/10.1016/j.dld.2009.09.002
Schütte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, Bretschneider T, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol. 2014;14(1):117. https://doi.org/10.1186/1471-230x-14-117 PMid:24990270 DOI: https://doi.org/10.1186/1471-230X-14-117
Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, et al. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 2008;4(5):647-60. https://doi.org/10.2217/14796694.4.5.647 PMid:18922122 DOI: https://doi.org/10.2217/14796694.4.5.647
Ismail BE, Cabrera R. Management of liver cirrhosis in patients with hepatocellular carcinoma. Chin Clin Oncol. 2013;2(4):34. PMid:25841913
Bartolomeo N, Trerotoli P, Serio G. Progression of liver cirrhosis to HCC: An application of hidden Markov model. BMC Med Res Methodol. 2011;11(1):38. https://doi.org/10.1186/1471-2288-11-38 DOI: https://doi.org/10.1186/1471-2288-11-38
Yang SH, Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on clear cell hepatocellular carcinoma. Pathol Inter. 1996;46(7):503-9. https://doi.org/10.1111/j.1440-1827.1996.tb03645.x PMid:8870006 DOI: https://doi.org/10.1111/j.1440-1827.1996.tb03645.x
Ge WS, Wang YJ, Wu JX, Fan JG, Chen YW, Zhu L. β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Mol Med Rep. 2014;9(6):2145-51. https://doi.org/10.3892/mmr.2014.2099 PMid:24691643 DOI: https://doi.org/10.3892/mmr.2014.2099
Ren YJ, Huang T, Yu HL, Zhang L, He QJ, Xiong ZF, et al. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein. J Huazhong Univ Sci Tech Med Sci. 2016;36(6):846-51. https://doi.org/10.1007/s11596-016-1673-9 PMid:27924522 DOI: https://doi.org/10.1007/s11596-016-1673-9
Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112(1):44-50. https://doi.org/10.1002/ijc.20279 PMid:15305374 DOI: https://doi.org/10.1002/ijc.20279
Damalas A, Kahan S, Shtutman M, Ben-Ze’ev A, Oren M. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 2001;20(17):4912-22. https://doi.org/10.1093/emboj/20.17.4912 PMid:11532955 DOI: https://doi.org/10.1093/emboj/20.17.4912
Gong XY, Ma N, Xu HX, Chen F, Huang XH, Wang Q. Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery. Oncol Lett. 2018;15(3):3796-805. https://doi.org/10.3892/ol.2018.7733 PMid:29467897 DOI: https://doi.org/10.3892/ol.2018.7733
Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghar W, et al. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol. 2010;176(1):472-81. https://doi.org/10.2353/ajpath.2010.090300 PMid:20008139 DOI: https://doi.org/10.2353/ajpath.2010.090300
Wang D, Luo L, Chen W, Chen LZ, Zeng WT, Li W, et al. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 2014;31(3):1199-204. https://doi.org/10.3892/or.2013.2946 PMid:24366206 DOI: https://doi.org/10.3892/or.2013.2946
Lu XY, Xi T, Lau WY, Dong H, Xian ZH, Yu H, et al. Pathobiological features of small hepatocellular carcinoma: Correlation between tumor size and biological behavior. J Canc Res Clin Oncol. 2011;137(4):567-75. https://doi.org/10.1007/s00432-010-0909-5 PMid:20508947 DOI: https://doi.org/10.1007/s00432-010-0909-5
Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, Cheng CC, et al. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastroenterol Surg. 2011;15(2):321-9. https://doi.org/10.1007/s11605-010-1373-x PMid:21061181Open Access Maced J Med Sci. 2021 Oct 21; 9(A):887-893. 893 DOI: https://doi.org/10.1007/s11605-010-1373-x
Downloads
Published
How to Cite
License
Copyright (c) 2021 Nur Rahadiani, Ignasia Andhini Retnowulan, Marini Stephanie, Diah Rini Handjari, Ening Krisnuhoni (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
